Phase 3 Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
Conditions: Type 2 Diabetes Mellitus Interventions: Drug: TG103; Drug: Dulaglutide Sponsors: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Metformin | Research | Study